Doctor-Led Webinar Sponsored by Perimeter Medical Imaging AI Highlights Developments in Intraoperative Specimen Imaging

0

Toronto, Ontario – (BUSINESS WIRE) – Perimeter Medical Imaging AI, Inc. (TSX-V: ROSA) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”), a medical technology company that brings cancer surgery to life with ultra-high definition, advanced real time Imaging tools for addressing the major medical needs announced today that a physician-led webinar organized by Perimeter as an industry event through the American Society of Breast Surgeons (ASBrS) is now available for playback on the Perimeter website.

Perimeter recently announced that it has received 510 (k) clearance from the US Food and Drug Administration (FDA) for its Optical Coherence Tomography (OCT) (v2.1) imaging system, which enables tissue microstructures to be used during surgical procedures by providing cross-sectional imaging. to be examined are cutting real-time edge visualization. Perimeter’s technology was developed in close collaboration with experienced doctors and clinicians to ensure optimal integration into current surgical workflows and to meet the urgent need for real-time images to support edge visualization. Perimeter is now actively stepping up its commercialization efforts to bring its OCT imaging system to the US market.

The ASBrS webinar, titled “The Next Generation in Surgical Sample Imaging with Future AI Enhancements,” is ideal for experienced breast surgeons studying how optical coherence tomography (OCT), a high-resolution imaging modality commonly used in ophthalmology and cardiology, is ideal for Edge visualization is useful during surgery. In addition, the panelists will provide insights into the possible future uses of artificial intelligence (AI) in the operating room and for sample imaging.

The respected medical panel consisted of key opinion leaders including:

  • Dr. med. Hank Schmidt, Associate Professor of Surgery, Mount Sinai Medical School, Dubin Breast Center, Tish Cancer Institute, New York, NY

  • Beth DuPree, MD, FACS, ABOIM, Medical Director, Oncology Service Line Centers in Northern Arizona, Healthcare in Northern Arizona, Sedona, AZ

  • Alastair Thompson, BSc (Hons), MBChB, MD, FRCS (Ed.), Professor and Chief, Department of Breast Surgery, Department of Surgical Oncology, Baylor College of Medicine, Houston, TX

Jeremy Sobotta, Perimeter’s Chief Executive Officer, stated, “With our recent 510 (k) clearance, we are focused on bringing our novel OCT imaging system to clinicians in the United States. We are grateful to all valued panelists who have shared with fellow ASBrS members their views on new developments in specimen imaging and the potential to lower re-excision rates, improve patient outcomes, and reduce healthcare costs with Perimeter’s transformative and disruptive technology. I encourage those interested in learning more to access the on-demand replay of this presentation. In parallel with our ongoing commercialization efforts, we are advancing our proprietary AI technology through clinical development as part of our ATLAS AI project to support the advancement of our next generation technology platform. ”

The webinar can be accessed on the Perimeter website at www.perimetermed.com or directly at https://oct.perimetermed.com/asbrs-webinar.

About Perimeter Medical Imaging AI, Inc.

Perimeter Medical Imaging AI (TSX-V: ROSA) (OTC: PYNKF) (FSE: 4PC) is a Toronto-based company headquartered in Dallas, Texas in the United States. Radiologists and pathologists for the visualization of microscopic tissue structures during a clinical procedure. Perimeter’s OCT Imaging Platform is a point-of-care imaging system that enables clinicians to obtain real-time, high-resolution, sub-surface image volumes (1-2 mm below the surface) of an excised tissue sample. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard nursing tissue assessment for decision making during the procedure can lead to better long-term patient outcomes and lower healthcare system costs. Perimeter’s OCT imaging platform has been approved by the FDA as an imaging tool for assessing the microstructure of excised human tissue by providing real-time, two-dimensional depth visualization in cross-section with image review manipulation software to identify and annotate regions of interest. In addition, Perimeter is developing advanced artificial intelligence and machine learning image assessment tools to improve review efficiency through its ATLAS AI project, made possible in part by a $ 7.4 million grant granted by Cancer Prevention and Research Institute of Texas (CPRIT), a leading government agency that funds cancer research.

The “PINK” perimeter ticker symbolizes the pink ribbons used by the Canadian Cancer Society and American Cancer Society during Breast Cancer Awareness Month. This underscores the company’s commitment to helping surgeons, radiologists and pathologists fight perimeter imaging technology for breast cancer, which is an estimated 30% of all cancer diagnoses in women this year.

Neither the TSX Venture Exchange nor its regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this press release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” ” And similar words and their negative form are used to identify forward-looking statements. Forward-looking information may relate to management’s future prospects and anticipated events or results and may include statements or information regarding the timing and results of clinical trials, the commercialization of Perimeter’s OCT imaging system, future financial condition, business strategy and strategic goals. Competitive conditions, research and development activities, projected costs and investments, financial results, research and clinical test results, taxes and plans and goals from or including perimeter. Without limitation, information about potential future development and commercialization activities and the terms of the options to be issued are forward-looking information. Forward-looking statements should not be taken as a guarantee of future performance or results and are not necessarily indicative of whether, or at what times, or at what times such future performance will be achieved. No assurance can be given that events anticipated from the forward-looking information will occur or will occur. Forward-looking information is based on information available at the time and / or in management’s good faith with respect to future events and is subject to known and unknown risks, uncertainties, assumptions and other unforeseeable factors, many of which are beyond Perimeter’s control . Such forward-looking statements reflect Perimeter’s current view of future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In forward-looking statements, Perimeter may make various material assumptions, including, but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from experiments; (iii) obtaining the necessary regulatory approvals; and (iv) general business, market and economic conditions. Other risks, uncertainties and assumptions include, but are not limited to, those that apply to Perimeters and describe the May 12, 2020 Joint Information Circular prepared in relation to the securities meetings held on June 17, 2020 The SEDAR Profile by Perimeter at www.sedar.com could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we draw your attention to the risk that our technology may not achieve the expected benefit in terms of surgical results. Perimeter does not intend or undertake any obligation to update or revise any forward-looking information in this press release to reflect later information, events or circumstances or otherwise, except as required by law.

Leave A Reply

Your email address will not be published.